Biogen Spinraza Treatment Delays Show COVID-19 Is Already Impacting Hospital Treatments
Biogen confirmed that some patients treated with Spinraza are temporarily having their dosing postponed as hospital systems brace for COVID-19, potentially a broader issue for the industry.
You may also be interested in...
The firm has stumped up $60m for Ionis’s preclinical antisense asset in spinal muscular atrophy, a potential successor to the slowing Spinraza, which also faces patent expiry in a few years.
Second quarter performance was better than expected, but commercial weaknesses show the need for R&D wins and M&A deals as Tecfidera generics and aducanumab uncertainty weigh on the company.
Biogen said some spinal muscular atrophy patients are currently being treated with Spinraza after receiving the Novartis gene therapy – its main competitor – so it will start a study of the risk/benefit in 2021.